Epstein-Barr Virus (EBV)-Induced B-Cell Proliferative Disorder after Chemotherapy in a Patient with Hemophagocytic Lymphohistiocytosis with Associated EBV-Induced T-cell Proliferation

J. Suzumiya,K. Ohshima,M. Kanda,Midori Kumagawa,M. Nagano,Masayuki Hirata,Y. Nawa,K. Tamura,M. Kikuchi
DOI: https://doi.org/10.3109/10428190009058512
2000-01-01
Abstract:We report a case of Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (LPD) which developed after chemotherapy for hemophagocytic lymphohistiocytosis (HLH), who had no history of immunodeficiency or familial X-linked LPD. In HLH, the presence of EBV in T-cells was confirmed by a combination of in situ hybridization (ISH) and immunostaining. Southern blot analysis using EBV-TR and immunoglobulin JH probes revealed oligoclonal proliferation of B-cells in each organ involved by abnormal B-lymphoid cells at autopsy. Combined ISH and immunostaining disclosed the presence of EBV in proliferating B-cells. Cytokine analysis during the period of T-cell activation in HLH revealed marked elevation of interferon (IFN) m¨, interleukin (IL)-10 and soluble IL-2 receptor (sIL-2R) and mild to moderate increases of tumor necrosis factor (TNF)-α were observed, while IFNm`, IL-10 and sIL-2R were elevated initially during the HLH phase, which then decreased as LPD developed and B-cell proliferation predominated. Immunosuppressive chemotherapy for HLH may then have allowed latent EBV in B lymphocytes to induce transformation and oligoclonal proliferation of B-cells, finally resulting in LPD. Mechanisms of EBV-induced cell proliferation remain unclear, but alteration of various cytokines may be responsible for it.
What problem does this paper attempt to address?